GENFIT (GNFT.PA)
FR0004163111 - Common Stock
Overall GNFT gets a fundamental rating of 5 out of 10. We evaluated GNFT against 74 industry peers in the Biotechnology industry. Both the profitability and the financial health of GNFT get a neutral evaluation. Nothing too spectacular is happening here. GNFT is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
GNFT had a negative operating cash flow in the past year.
GNFT had negative earnings in 4 of the past 5 years.
In the past 5 years GNFT reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of GNFT (11.43%) is better than 98.55% of its industry peers.
Looking at the Return On Equity, with a value of 22.87%, GNFT belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
GNFT's Return On Invested Capital of 11.07% is amongst the best of the industry. GNFT outperforms 89.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROIC | 11.07% |
ROA(3y)-1.25%
ROA(5y)-15.15%
ROE(3y)-3.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.51%, GNFT belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
GNFT has a Operating Margin of 28.39%. This is amongst the best in the industry. GNFT outperforms 94.20% of its industry peers.
With an excellent Gross Margin value of 97.41%, GNFT belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y4.62%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so GNFT is still creating some value.
The number of shares outstanding for GNFT remains at a similar level compared to 1 year ago.
GNFT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
GNFT has an Altman-Z score of -0.07. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-0.07) which is in line with its industry peers.
GNFT has a Debt/Equity ratio of 0.61. This is a neutral value indicating GNFT is somewhat dependend on debt financing.
GNFT has a worse Debt to Equity ratio (0.61) than 60.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.07 |
ROIC/WACC1.56
WACC7.1%
2.3 Liquidity
A Current Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
The Current ratio of GNFT (3.74) is better than 68.12% of its industry peers.
GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GNFT (3.74) is better than 68.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 153.62% over the past year.
Looking at the last year, GNFT shows a very strong growth in Revenue. The Revenue has grown by 182.34%.
The Revenue has been growing by 38.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.19%
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y38.49%
Sales Q2Q%413.61%
3.2 Future
The Earnings Per Share is expected to grow by 25.73% on average over the next years. This is a very strong growth
GNFT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.20% yearly.
EPS Next Y379.58%
EPS Next 2Y-69.7%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year54.53%
Revenue Next 2Y-23.27%
Revenue Next 3Y-11.25%
Revenue Next 5Y28.2%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.41, the valuation of GNFT can be described as reasonable.
Based on the Price/Earnings ratio, GNFT is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of GNFT to the average of the S&P500 Index (27.54), we can say GNFT is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.41 | ||
| Fwd PE | N/A |
4.2 Price Multiples
92.75% of the companies in the same industry are more expensive than GNFT, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.04 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of GNFT may justify a higher PE ratio.
A more expensive valuation may be justified as GNFT's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y-69.7%
EPS Next 3Y25.73%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENFIT
EPA:GNFT (12/24/2024, 7:00:00 PM)
3.48
+0.01 (+0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.11%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap173.52M
Analysts90.77
Price Target9.55 (174.43%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.81%
PT rev (3m)0.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)37.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.41 | ||
| Fwd PE | N/A | ||
| P/S | 2.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.78 | ||
| P/tB | 3.44 | ||
| EV/EBITDA | 7.04 |
EPS(TTM)0.37
EY10.63%
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS1.68
BVpS1.95
TBVpS1.01
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROCE | 15.06% | ||
| ROIC | 11.07% | ||
| ROICexc | 18.13% | ||
| ROICexgc | 35.23% | ||
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% | ||
| FCFM | N/A |
ROA(3y)-1.25%
ROA(5y)-15.15%
ROE(3y)-3.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y4.62%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.34 | ||
| Cap/Depr | 73.22% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -0.07 |
F-Score6
WACC7.1%
ROIC/WACC1.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.19%
EPS Next Y379.58%
EPS Next 2Y-69.7%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y38.49%
Sales Q2Q%413.61%
Revenue Next Year54.53%
Revenue Next 2Y-23.27%
Revenue Next 3Y-11.25%
Revenue Next 5Y28.2%
EBIT growth 1Y173.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.04%
EBIT Next 3Y-8.48%
EBIT Next 5YN/A
FCF growth 1Y-153.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.78%
OCF growth 3YN/A
OCF growth 5YN/A